9 nov 2020 - The FDA grants an EUA for Eli Lilly’s monoclonal antibody treatment, bamlanivimab. Lilly showed that hospitalizations in COVID-19 patients decreased within 28 days, indicating that it prevents severe forms of the disease when administered quickly.
Ajouté au bande de temps:
Date:
9 nov 2020
Maintenaint
~ Il y a 3 ans et 7 mois
